ALZHEON
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associated with neurodegeneration. They have a distinct ability to make success advances in the challenging field of therapeutics for Alzheimer’s and other neurodegenerative disorders.
ALZHEON
Industry:
Biotechnology Clinical Trials Health Care Therapeutics
Founded:
2013-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.alzheon.com
Total Employee:
11+
Status:
Active
Contact:
+1 857 214-7242
Email Addresses:
[email protected]
Total Funding:
136.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Current Advisors List
Current Employees Featured
Founder
Investors List
National Institute on Aging
National Institute on Aging investment in Grant - Alzheon
Ally Bridge Group
Ally Bridge Group investment in Series B - Alzheon
Scott H. Cohen
Scott H. Cohen investment in Series A - Alzheon
Ally Bridge Group
Ally Bridge Group investment in Series A - Alzheon
Key Employee Changes
Official Site Inspections
http://www.alzheon.com Semrush global rank: 2.92 M Semrush visits lastest month: 5.58 K
- Host name: 61.171.211.130.bc.googleusercontent.com
- IP address: 130.211.171.61
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Alzheon"
Alzheon - Wikipedia
Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, a veteran of Alzheimer's drug programs, who serves as president and CEO of the organization. Alzheon completed a $10 million Series A round of financing in April 2015 and started the Phase lb bridging clinical program for ALZ-801, which was completed in July 2016. In August 2018, Alzheon appointed former IVAX President Neil Flanzraich, JD, as Vice Chairma…See details»
Alzheon - Crunchbase Company Profile & Funding
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline …See details»
Alzheon Management Team - Alzheon | Preserving Future Memories
Management Team Dr. Tolar serves as Founder, President & CEO of Alzheon. Prior to founding Alzheon in June 2013, Dr. Tolar held executive positions in several life sciences companies, …See details»
Alzheon Company Profile 2024: Valuation, Funding & Investors
When was Alzheon founded? Alzheon was founded in 2013. Where is Alzheon headquartered? Alzheon is headquartered in Framingham, MA. What is the size of Alzheon? Alzheon has 31 …See details»
Alzheon, Inc. | Preserving Future Memories | LinkedIn
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.See details»
Alzheon - Org Chart, Teams, Culture & Jobs - The Org
View Alzheon's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Alzheon - Funding, Financials, Valuation & Investors - Crunchbase
Alzheon is funded by 4 investors. Alerce Medical Technology Partners and National Institute on Aging are the most recent investors. Alzheon has a post-money valuation in the range of $50M …See details»
Alzheon Board of Directors - Alzheon | Preserving …
Board of Directors Executive Chairman of Cantex Pharmaceuticals, Inc. Former Vice Chairman and President of IVAX Corporation Mr. Flanzraich brings to Alzheon more than 30 years of executiveSee details»
Alzheon Company Profile - Office Locations, Competitors ... - Craft
Alzheon is a biotechnology company focused on womanchild brain health, memory and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative …See details»
Company Alzheon, Inc. - MarketScreener.com
May 31, 2013 Alzheon Inc is a United States-based clinical-stage biopharmaceutical company. The company is developing medicines for patients suffering from alzheimer's disease and …See details»
Alzheon - VentureRadar
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical …See details»
Alzheon - Contacts, Employees, Board Members, Advisors & Alumni
Alzheon has 10 current employee profiles, including Chief Financial Officer Ken Mace. Alzheon has 4 board members and advisors, including Jean-Pierre Garnier . ContactsSee details»
Alzheon CEO and Key Executive Team | Craft.co
Alzheon's Founder, President, CEO and Director is Martin Tolar. Other executives include Neil Flanzraich, Executive Chairman of the Board of Directors; Susan Abushakra, Chief Medical …See details»
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and ...
FRAMINGHAM, Mass., December 05, 2023--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients …See details»
About - Alzheon | Preserving Future Memories
About Alzheon Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of …See details»
Alzheimer's Drug Developer Alzheon Closes $100M Series E …
Jun 12, 2024 Alzheon CEO Martin Tolar, MD, PhD. Alzheon says it expects to fund the completion of a pivotal Phase III trial and regulatory filings later this year for its lead candidate, …See details»
Alzheon - Overview, News & Similar companies | ZoomInfo.com
Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical …See details»
Alzheimer’s Drug Developer Alzheon Closes $100M Series E …
By Alex Philippidis | June 12, 2024 Credit: koto_feja/Getty Images Alzheon says it expects to fund the completion of a pivotal Phase III trial and regulatory filings later this year for its lead …See details»
Alzheon News - Alzheon | Preserving Future Memories
In the News Press ReleasesSee details»